Abstract OT3-06-01: SHERBOC: A double-blind, placebo-controlled, phase 2 trial of seribantumab (MM-121) plus fulvestrant in postmenopausal women with hormone receptor-positive, heregulin positive, HER2 negative metastatic breast cancer whose disease progressed after prior systemic therapy
暂无分享,去创建一个
Hong Zhang | T. Bloom | G. Finn | J. Ettl | A. Kudla | S. Mathews | P. Kaufman | J. Richards | J. Llorin-Sangalang | M. Pipas | Ac Pinto | Aa Zalutskaya